Advanced in Embryonal Tumor with Multilayered Rosettes

Dr. Carl J. Koschmann

Pediatric Hematology Oncology
1500 E Medical Center Dr, 
Ann Arbor, MI 
Advanced in Embryonal Tumor with Multilayered Rosettes
1500 E Medical Center Dr, 
Ann Arbor, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Carl Koschmann is a Pediatric Hematologist Oncology provider in Ann Arbor, Michigan. Dr. Koschmann is rated as an Advanced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Glioma, Brain Stem Cancer, and Embryonal Tumor with Multilayered Rosettes.

His clinical research consists of co-authoring 118 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Embryonal Tumor with Multilayered Rosettes.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in WA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UPMC
  • EPO
  • PPO
View 3 Less Insurance Carriers -

Locations

1500 E Medical Center Dr, Ann Arbor, MI 48109

Additional Areas of Focus

Dr. Koschmann has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Procedure, Radiation, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
Enrollment Status: Approved_for_marketing
Publish Date: August 20, 2025
Intervention Type: Drug
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drug: Mirdametinib
Study Phase: Phase 2
ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas
ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas
Enrollment Status: Terminated
Publish Date: February 14, 2025
Intervention Type: Drug
Study Drug: ONC201
Study Phase: Phase 1
A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2024
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Dasatinib in Combination With Everolimus for Children With Gliomas Harboring PDGFR Alterations
A Phase 2 Study of Dasatinib in Combination With Everolimus for Children With Gliomas Harboring PDGFR Alterations
Enrollment Status: Terminated
Publish Date: October 05, 2022
Intervention Type: Drug
Study Drugs: Dasatinib, Everolimus
Study Phase: Phase 2
An Early Phase 1 Trial of Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma
An Early Phase 1 Trial of Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma
Enrollment Status: Withdrawn
Publish Date: November 27, 2019
Intervention Type: Drug, Procedure
Study Phase: Early Phase 1
A Phase 2 Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas Harboring H3.3 or H3.1 K27M Mutation
A Phase 2 Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas Harboring H3.3 or H3.1 K27M Mutation
Enrollment Status: Withdrawn
Publish Date: August 19, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

115 Total Publications

Current Landscape of Preclinical Models for Pediatric Gliomas: Clinical Implications and Future Directions.
Current Landscape of Preclinical Models for Pediatric Gliomas: Clinical Implications and Future Directions.
Journal: Cancers
Published: April 30, 2025
Similar Doctors
Elite in Embryonal Tumor with Multilayered Rosettes
Dr. Gregory A. Yanik
Pediatric Hematology Oncology
Elite in Embryonal Tumor with Multilayered Rosettes
Dr. Gregory A. Yanik
Pediatric Hematology Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (0.2 miles away)
Languages Spoken:
English
See accepted insurances

Gregory Yanik is a Pediatric Hematologist Oncology provider in Ann Arbor, Michigan. Dr. Yanik is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Graft Versus Host Disease (GvHD), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplant.

Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Rajen J. Mody
Pediatric Hematology Oncology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Rajen J. Mody
Pediatric Hematology Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr, Suite 0331, 
Ann Arbor, MI 
 (0.4 miles away)
734-936-5738
Languages Spoken:
English
See accepted insurances

Rajen Mody is a Pediatric Hematologist Oncology provider in Ann Arbor, Michigan. Dr. Mody is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Infantile Neutropenia, Glioma, and Bone Marrow Aspiration.

Advanced in Embryonal Tumor with Multilayered Rosettes
Dr. Santhosh A. Upadhyaya
Pediatric Hematology Oncology
Advanced in Embryonal Tumor with Multilayered Rosettes
Dr. Santhosh A. Upadhyaya
Pediatric Hematology Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr, Suite 0331, 
Ann Arbor, MI 
 (0.4 miles away)
734-936-5738
Languages Spoken:
English
See accepted insurances

Santhosh Upadhyaya is a Pediatric Hematologist Oncology provider in Ann Arbor, Michigan. Dr. Upadhyaya is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Rhabdoid Tumor, Teratoma of the Mediastinum, Glioma, Medulloblastoma, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Koschmann's expertise for a condition
ConditionClose
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile